Cipla launches Yurpeak, its obesity and type 2 diabetes drug

MUMBAI: Cipla has launched Yurpeak, its version of tirzepatide, marking a major push into the fast-growing market for obesity and type 2 diabetes treatments. The therapy, licensed from Eli Lilly, is the second tirzepatide brand cleared for India after the regulator approved Lilly’s own version.

Tirzepatide is the first dual agonist targeting GIP and GLP-1 receptors and is prescribed alongside diet and exercise for adults with type 2 diabetes or chronic weight-management needs. Yurpeak will be sold in Cipla’s KwikPen device in six strengths: 2.5 mg to 15 mg, allowing precise weekly dosing. It will be priced on par with Lilly’s Mounjaro.

Cipla global chief operating officer Achin Gupta, said the launch represents a “transformative moment” in addressing India’s soaring burden of obesity and diabetes. He added that Cipla would apply its scale and chronic-care expertise to widen access to globally benchmarked therapies.

Cipla plans to distribute Yurpeak nationwide, extending availability beyond large cities through its extensive network. Lilly will manufacture the drug, while Cipla handles promotion and distribution.

The company will back the rollout with patient-support initiatives covering dosage, self-injection and responsible use, in line with its focus on evidence-based communication and long-term wellness.